Integral Health Asset Management LLC Buys 40,000 Shares of Nurix Therapeutics, Inc. $NRIX

Integral Health Asset Management LLC increased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,000 shares of the company’s stock after acquiring an additional 40,000 shares during the quarter. Integral Health Asset Management LLC owned about 0.46% of Nurix Therapeutics worth $3,234,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Nurix Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 4,488,776 shares of the company’s stock valued at $41,476,000 after buying an additional 23,269 shares during the period. Vestal Point Capital LP lifted its position in Nurix Therapeutics by 77.7% during the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock valued at $22,780,000 after purchasing an additional 874,448 shares during the last quarter. Geode Capital Management LLC grew its stake in Nurix Therapeutics by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,881,960 shares of the company’s stock worth $21,437,000 after buying an additional 157,592 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Nurix Therapeutics by 11.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock worth $14,391,000 after buying an additional 165,841 shares in the last quarter. Finally, Amova Asset Management Americas Inc. increased its stake in Nurix Therapeutics by 12.1% in the third quarter. Amova Asset Management Americas Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after acquiring an additional 168,205 shares during the last quarter.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the transaction, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. The trade was a 7.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the transaction, the insider directly owned 83,672 shares of the company’s stock, valued at approximately $1,388,955.20. The trade was a 5.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NRIX shares. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the stock an “overweight” rating in a report on Thursday, January 8th. Royal Bank Of Canada increased their target price on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, January 29th. Wells Fargo & Company decreased their target price on shares of Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Thursday, January 29th. Stifel Nicolaus lifted their price target on Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Finally, Truist Financial began coverage on Nurix Therapeutics in a research note on Monday, November 24th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $15.04 on Friday. The stock has a market cap of $1.55 billion, a P/E ratio of -4.95 and a beta of 1.96. The stock has a 50 day simple moving average of $16.96 and a two-hundred day simple moving average of $14.41. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The business had revenue of $13.58 million for the quarter, compared to the consensus estimate of $13.41 million. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.